Drug intelligence / Profile preview

AYUB 15

Development stage: Preclinical
Lead developer: AYUB R&D
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

AYUB 15 is an enriched essential oil extract derived from *Boswellia sacra* (frankincense), currently in preclinical development by AYUB R&D. The drug is being investigated for its potential antineoplastic properties, specifically targeting breast cancer and bladder cancer. *Boswellia sacra* extracts are known to contain various bioactive compounds, including boswellic acids and specific terpenes, which have demonstrated pro-apoptotic and anti-proliferative effects in various cancer cell lines. AYUB 15 represents a specialized formulation designed to enhance these therapeutic effects.

Other names: enriched Boswellia sacra essential oil extract

Beyond the preview

Go deeper on AYUB 15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AYUB 15.

Explore the full profile